TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems Limited has announced significant progress in its MagSense® HER2 Breast Cancer diagnostic imaging program, with the commencement of manufacturing for the Phase 2 clinical trial. The company has also secured $3.5 million in funding and appointed Dr. Nina Webster as a Non-Executive Director to strengthen its leadership team. Additionally, Imagion has initiated a collaboration with Wayne State University to optimize imaging protocols, supported by Siemens Healthineers, which could enhance the diagnostic utility of its molecular MRI technology.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a company focused on enhancing healthcare outcomes through early cancer detection using its proprietary MagSense® imaging technology.
Average Trading Volume: 5,060,608
Technical Sentiment Signal: Sell
Current Market Cap: A$3.94M
See more data about IBX stock on TipRanks’ Stock Analysis page.